Provided by Tiger Trade Technology Pte. Ltd.

Fidelity MSCI Health Care Index ETF

83.24
-0.7650-0.91%
Volume:49.97K
Turnover:4.16M
Market Cap:3.50B
PE:- -
High:83.51
Open:83.45
Low:83.11
Close:84.00
52wk High:85.46
52wk Low:64.30
Shares:42.00M
Float Shares:42.00M
Volume Ratio:1.51
T/O Rate:0.12%
Dividend:1.02
Dividend Rate:1.22%
ROE:--
ROA:--
PB:--
PE(LYR):- -

Loading ...

Wuhan Dazhong Dental Proposes Wang Hong as Executive Director to Replace Guo Jiaping

Reuters
·
1 hour ago

J&J EVP, Worldwide Chair MedTech Timothy Schmid Disposes of 33,597 Common Shares Worth $9.23 Million

Reuters
·
1 hour ago

Dow Jones Top Company Headlines at 9 am ET: EQT to Buy Insurance Broker McGill in $2 Billion Deal | Tesla-Challenging ...

Dow Jones
·
1 hour ago

Scotiabank Remains a Buy on AbbVie (ABBV)

TIPRANKS
·
2 hours ago

UnitedHealth (UNH) Gets a Buy from Bernstein

TIPRANKS
·
3 hours ago

Wells Fargo Adjusts Price Target on Merck & Co. to $170 From $150, Keeps Overweight Rating

MT Newswires Live
·
5 hours ago

AbbVie Closes $10.9B Takeover of Apogee, Its Largest Deal Since 2019, With Earnings Lift Expected From 2032

Stock News
·
12 hours ago

Perrigo Co. PLC Stock Underperforms Thursday When Compared to Competitors

Dow Jones
·
17 hours ago

Eli Lilly Stock (LLY) Gets a Bullish Note from JPMorgan Chase

TIPRANKS
·
19 hours ago

Sector Update: Healthcare Stocks Higher Thursday Afternoon

MT Newswires Live
·
20 hours ago

Healthcare Stocks Pick up Steam as Investors Play Offense and Defense

Dow Jones
·
20 hours ago

Eisai’s Lenvima Combo Trial in Liver Cancer Ends With Mixed but Market-Relevant Results

TIPRANKS
·
22 hours ago

Summit Therapeutics Says it is Beating Merck with Its Cancer Drug

Dow Jones
·
22 hours ago

AbbVie's Phase 3 Study of Etentamig in Multiple Myeloma Meets Dual Primary Endpoints

MT Newswires Live
·
Yesterday

AbbVie Says Blood Cancer Drug Met Dual Primary Endpoints in Phase 3 Study

Dow Jones
·
Yesterday

AbbVie announces Phase 3 Cervino study met dual primary endpoints of ORR, PFS

TIPRANKS
·
Yesterday

AbbVie's Blood Cancer Drug Meets Late-Stage Trial Goals

Reuters
·
Yesterday

Abbvie - Phase 3 Cervino Study Met Dual Primary Endpoints; Full Results to be Presented Sept 23-26

THOMSON REUTERS
·
Yesterday

Abbvie - Etentamig Demonstrates Low Rates of Cytokine Release Syndrome and Fatal Infections

THOMSON REUTERS
·
Yesterday

Abbvie - Etentamig Achieves 74% Orr and 60% Risk Reduction in Phase 3 Cervino Trial

THOMSON REUTERS
·
Yesterday